pimecrolimus + paclitaxel

Pimecrolimus + paclitaxel** is a combination of two distinct pharmaceutical drugs: - **Pimecrolimus** is an immunomodulatory agent primarily used topically for inflammatory skin disorders. It acts by inhibiting T-cell activation and cytokine release through high-affinity binding to FKBP-12, inhibiting calcineurin, and thus blocking early cytokine transcription, especially Interleukin-2, interferon gamma, Interleukin-4, and Interleukin-10. It also inhibits release of inflammatory mediators from mast cells[3]. - **Paclitaxel** is an antineoplastic (anticancer) agent widely used for several cancers including ovarian and breast cancer. Its mechanism is hyper-stabilization of microtubules: it binds to the β subunit of tubulin, promotes microtubule assembly, prevents their depolymerization, and interferes with mitosis, thereby leading to cell cycle arrest and apoptosis[2]. The combination "pimecrolimus + paclitaxel" is not an established single-brand product, but rather refers to concurrent administration of the two drugs. The risk or severity of adverse effects may be increased when pimecrolimus is combined with paclitaxel, though the exact nature of interaction is not elaborated in available sources[3][2][1].